

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	3856879
<b>Application Number:</b>	10520207
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	9839
<b>Title of Invention:</b>	G-type peptides to ameliorate atherosclerosis
<b>First Named Inventor/Applicant Name:</b>	Alan M. Fogelman
<b>Customer Number:</b>	22434
<b>Filer:</b>	Tom Hunter/Swapnali Joshi
<b>Filer Authorized By:</b>	Tom Hunter
<b>Attorney Docket Number:</b>	UCLA-P013X1.US
<b>Receipt Date:</b>	28-AUG-2008
<b>Filing Date:</b>	23-DEC-2005
<b>Time Stamp:</b>	16:19:13
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$930
RAM confirmation Number	2225
Deposit Account	504480
Authorized User	

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
-----------------	----------------------	-----------	----------------------------------	------------------	------------------

1	Request for Continued Examination (RCE)	UCLAP013X1_RCE_am3.pdf	33795 8fff9228374150f85686dfff6f31c4728a4c3dffa	no	2
<b>Warnings:</b>					
This is not a USPTO supplied RCE SB30 form.					
<b>Information:</b>					
2		UCLAP013X1_OAR1_am3.pdf	64182 d267a6f3596d753c7a13075dc260193eb659a6dd	yes	15
	<b>Multipart Description/PDF files in .zip description</b>				
	<b>Document Description</b>		<b>Start</b>	<b>End</b>	
	Amendment Submitted/Entered with Filing of CPA/RCE		1	1	
	Claims		2	13	
	Applicant Arguments/Remarks Made in an Amendment		14	15	
<b>Warnings:</b>					
<b>Information:</b>					
3	Information Disclosure Statement Letter	UCLAP013X1US_IDS_trans_wAm3_082808.pdf	23653 03cee1c65fa28d561c8c54833cfa1e17c860f93	no	1
<b>Warnings:</b>					
<b>Information:</b>					
4	Information Disclosure Statement (IDS) Filed (SB/08)	UCLAP013X1US_1449_IDS_082808.pdf	26744 58dedb12a8582e9974b064527b764555efdc3445d	no	1
<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
5	NPL Documents	1-Art_XP002378357_Apol-ovarian-tumour.pdf	72887 e97918183a91db240a388d32eb2a71827db91c24	no	1
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	2-Art_XP002378360_Human-Apol-A-IV-Fragment.pdf	30965 3109b2903ce7bcbfd999c2e863ed048b5fb6cc020	no	1
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	3-Art_XP002378358_Human-Apol-CIII.pdf	50279 49453f2252c386669cce05dec7fef2d2d2b2d63f	no	1

Warnings:					
Information:					
8	NPL Documents	4-Art_XP002378359_Human-Polypeptide.pdf	40185	no	1
			e084bd783c16eb1da546cf230a1a52466f9c0692		
Warnings:					
Information:					
9	NPL Documents	5-UCLAP013X1_OA_01_09_04.pdf	1447595	no	27
			26029992069c64103f5cb91aab79eeb268ba6116		
Warnings:					
Information:					
10	NPL Documents	6-UCLAP013X1_OA_09_02_04.pdf	250355	no	6
			1b86a928f45fdbcbab615370c6e224c97d77a437a		
Warnings:					
Information:					
11	NPL Documents	7-UCLAP013X1_NOA_12_21_04.pdf	1399485	no	22
			33b03aa2a123e02d9b0d61cf21becc8c1717c73f		
Warnings:					
Information:					
12	NPL Documents	8-UCLAP013X1-AU_OA_09_10_07.pdf	73686	no	2
			26a377f7238947bfd97fb4d4fa78edbd361cbbaf		
Warnings:					
Information:					
13	NPL Documents	9-UCLAP013X1-CN_OA_01_06_06.pdf	262647	no	5
			a2d109cbb85beaab99a86995201ab0937379e0f8		
Warnings:					
Information:					
14	NPL Documents	10-UCLAP013X1-CN_OA_01_22_07.pdf	117480	no	3
			6c6dc27098f10afa2a9a48f473b04adce66351e5		
Warnings:					
Information:					
15	NPL Documents	11-UCLAP013X1-CN_OA_08_03_07.pdf	667840	no	11
			fb536bda5d3cf7f8867cf15923fe23d0521f75aa		
Warnings:					
Information:					
16	NPL Documents	12-UCLAP013X1-IN_Exam-Rpt_04_09_07.pdf	7148040	no	25
			ec3b52d9e63b52e482ab3b521cbff7866ab08f00		

<b>Warnings:</b>					
<b>Information:</b>					
17	Fee Worksheet (PTO-06)	fee-info.pdf	31975	no	2
			dd978442916187b03bf58f2a0b6c767d3439a5c0		
<b>Warnings:</b>					
<b>Information:</b>					
Total Files Size (in bytes):			11741793		
<p><b>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</b></p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>  <b>If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</b></p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>  <b>If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</b></p> <p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b>  <b>If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</b></p>					